Preferred Label : Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025;
NCIt synonyms : pHLAre (TM) CLSP-1025; Precise HLA Redirecting Engager CLSP-1025; p53 R175H/HLA-A*02:01-specific T-cell Engager CLSP-1025; Anti-p53 R175H TCE CLSP-1025; Bispecific T-cell Engager Anti-HLA-A*02:01/p53 R175H CLSP-1025; Bispecific TCE CLSP-1025; Anti-p53 R175H/CD3 Fusion Protein CLSP-1025; Anti-p53 R175H T-cell Engager CLSP-1025;
NCIt definition : An asymmetric bispecific single-chain diabody (scDb) Fc fusion protein and T-cell
engager (TCE) directed against the human TP53 (p53) R175H mutant peptide (p53(R175H)168-176)
bound to human leukocyte antigen (HLA)-A*02:01 (HLA-A*02:01) and the T-cell-specific
antigen CD3epsilon (CD3e), with potential immunostimulating and antineoplastic activities.
Upon administration, anti-HLA-A*02:01/p53 R175H bispecific TCE CLSP-1025 specifically
targets and binds to CD3 on cytotoxic T-lymphocytes (CTLs) with its anti-CD3 domain
and the p53(R175H)168-176 mutant peptide bound to HLA-A*02:01 expressed on tumor cells
with its anti-peptide HLA (pHLA) domain. This activates and redirects CTLs to HLA-A*02:01/p53
R175H-expressing tumor cells, which results in the CTL-mediated cell death of these
p53 R175H-expressing tumor cells. p53, a tumor suppressor gene, is mutated in many
tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.;
Molecule name : CLSP 1025; CLSP-1025;
Origin ID : C215299;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
